The therapy pairing neratinib with RSL3 enhances lipid peroxidation and mitochondrial impairment, resulting in increased ferroptotic cell death, providing a promising strategy for improving outcomes in patients with HER-2-positive breast cancer who may not adequately respond to standard treatments (Hu et al., 2024; Park et al., 2023). The gene discussed is ERBB2; the disease is breast carcinoma.